Metropolis Healthcare Ltd share Price

Metropolis Healthcare announced Q1FY24 results:

• Core business revenue growth stood at Rs 271 crore, up 12% YoY with 9% volume growth & 3% RPT growth
• Core business patients stood at 2.7 million with a growth of 9% YoY
• Total B2C revenue in grew by 13% for Q1FY24 YoY with volume growth of 9%
• EBIDTA before network expansion stood at 25.3%
• Premium wellness segments revenue grew by 27% & volumes grew by 38% indicating strong brand equity & consumer trust on Metropolis.
• Contribution of premium wellness stood at 15%
• B2C revenue growth in Mumbai stood at 15% on account of our strong brand presence & dense network

“In Q1FY24, the core business revenues grew by 12% YoY, reflecting a consistent trend of double-digit growth over the past five quarters for its core revenues. Total Revenues for Q1FY24 were down by 1% primarily on account of a large B2G contract insourced by the Government & a high base of Covid & Allied tests. The company remains optimistic about scaling up revenue in the upcoming quarters, indicating positive operating leverage play.

B2C revenue grew by 13% YoY with Mumbai revenues for B2C growing by over 15%. Metropolis has witnessed growth across the test mix in B2C markets with Specialised and Wellness segments growing by 15% & 19% respectively on a YoY basis.

Going forward, the company focuses on network expansion, increasing doctor connections, growing specialised & wellness segments, and upgrading IT infrastructure to enhance the consumer experience. We firmly believe that Metropolis is in an advantageous position to achieve a higher market share across various geographies and surpass industry growth", said Ameera Shah, Promoter and Managing Director, Metropolis Healthcare.

Result PDF